Vonjo™ (pacritinib) has received U.S. FDA approval to treat intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis in adults who have a platelet count below 50 × 109/L.
- Vonjo is a novel oral kinase inhibitor that acts against enzymes in the body that may contribute to myelofibrosis, a rare bone marrow cancer. In myelofibrosis, scar tissue replaces healthy bone marrow and interferes with production of red blood cells, white blood cells, and platelets.
- Recommended dosing is two 100mg capsules taken twice daily by
- CTI BioPharma, the manufacturer, has announced that Vonjo will be available at a wholesale acquisition cost (WAC) of $19,500 per month.
